Endogenous N-acyl-dopamines induce COX-2 expression in brain endothelial cells by stabilizing mRNA through a p38 dependent pathway

Biochemical Pharmacology

Volumn 79, Issue 12, 2010, Pages 1805-1814

  Navarrete, Carmen M ^a   Pérez, Moisés ^a   de Vinuesa, Amaya García ^a   Collado, Juan A ^a   Fiebich, Bernd L ^c   Calzado, Marco A ^a,b   Muñoz, Eduardo ^a,b  

^a Universidad de Cordoba   (Spain)

^b Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

COX 2; Endothelial cells; MPGES 1; N Arachidonoyl dopamine; P38 MAPK

Indexed keywords

CANNABINOID 1 RECEPTOR; CYCLOOXYGENASE 2; DOPAMINE DERIVATIVE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; N ACYL DOPAMINE; N ARACHIDONOYL DOPAMINE; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D2; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BRAIN; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ARACHIDONIC ACIDS; BRAIN; CELL LINE; CYCLOOXYGENASE 2; DOPAMINE; ENDOTHELIAL CELLS; ENZYME INDUCTION; MAP KINASE SIGNALING SYSTEM; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER;

EID: 77951289963     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.02.014     Document Type: Article

References (72)

1. De Petrocellis L., Melck D., Bisogno T., Di Marzo V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 2000, 108:191-209.
2. Di Marzo V., Bisogno T., De Petrocellis L. Endocannabinoids: new targets for drug development. Curr Pharm Des 2000, 6:1361-1380.
3. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., Bisogno T. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 2002, 66:377-391.
4. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.
5. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000, 129:227-230.
6. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
7. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002, 99:8400-8405.
8. Chu C.J., Huang S.M., De Petrocellis L., Bisogno T., Ewing S.A., Miller J.D., et al. N-Oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 2003, 278:13633-13639.
9. Toth A., Kedei N., Wang Y., Blumberg P.M. Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat. Life Sci 2003, 73:487-498.
10. Bisogno T., Melck D., Bobrov M., Gretskaya N.M., Bezuglov V.V., De Petrocellis L., et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000, 351(Pt 3):817-824.
11. Harrison S., De Petrocellis L., Trevisani M., Benvenuti F., Bifulco M., Geppetti P., et al. Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. Eur J Pharmacol 2003, 475:107-114.
12. O'Sullivan S.E., Kendall D.A., Randall M.D. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 2004, 141:803-812.
13. Sancho R., Macho A., de La Vega L., Calzado M.A., Fiebich B.L., Appendino G., et al. Immunosuppressive activity of endovanilloids: N-arachidonoyl-dopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J Immunol 2004, 172:2341-2351.
14. Bobrov M.Y., Lizhin A.A., Andrianova E.L., Gretskaya N.M., Frumkina L.E., Khaspekov L.G., et al. Antioxidant and neuroprotective properties of N-arachidonoyldopamine. Neurosci Lett 2008, 431:6-11.
15. Navarrete C.M., Fiebich B.L., de Vinuesa A.G., Hess S., de Oliveira A.C., Candelario-Jalil E., et al. Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso-PGF formation in primary glial cells. J Neurochem 2009, 109:452-464.
16. Pryce G., Ahmed Z., Hankey D.J., Jackson S.J., Croxford J.L., Pocock J.M., et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126:2191-2202.
17. Malfitano A.M., Matarese G., Pisanti S., Grimaldi C., Laezza C., Bisogno T., et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J Neuroimmunol 2006, 171:110-119.
18. Achiron A., Miron S., Lavie V., Margalit R., Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000, 102:26-31.
19. Tseng C.F., Iwakami S., Mikajiri A., Shibuya M., Hanaoka F., Ebizuka Y., et al. Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-beta-phenethylamine and N-acyldopamine derivatives. Chem Pharm Bull (Tokyo) 1992, 40:396-400.
20. Bezuglov V.V., Manevich E.M., Archakov A.V., Bobrov M., Kuklev D.V., Petrukhina G.N., et al. Artificially functionalized polyenoic fatty acids-a new lipid bioregulators. Bioorg Khim 1997, 23:211-220.
21. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J 1998, 12:1063-1073.
22. Cao C., Matsumura K., Shirakawa N., Maeda M., Jikihara I., Kobayashi S., et al. Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors. Eur J Neurosci 2001, 13:1781-1790.
23. Caughey G.E., Cleland L.G., Gamble J.R., James M.J. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem 2001, 276:37839-37845.
24. Moolwaney A.S., Igwe O.J. Regulation of the cyclooxygenase-2 system by interleukin-1beta through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells. Brain Res Mol Brain Res 2005, 137:202-212.
25. Mark K.S., Trickler W.J., Miller D.W. Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 2001, 297:1051-1058.
26. Schmidley J.W., Dadson J., Iyer R.S., Salomon R.G. Brain tissue injury and blood-brain barrier opening induced by injection of LGE2 or PGE2. Prostaglandins Leukot Essent Fatty Acids 1992, 47:105-110.
27. Trickler W.J., Mayhan W.G., Miller D.W. Brain microvessel endothelial cell responses to tumor necrosis factor-alpha involve a nuclear factor kappa B (NF-kappaB) signal transduction pathway. Brain Res 2005, 1048:24-31.
28. de Vries H.E., Blom-Roosemalen M.C., van Oosten M., de Boer A.G., van Berkel T.J., Breimer D.D., et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996, 64:37-43.
29. Jakobsson P.J., Thoren S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999, 96:7220-7225.
30. Tanikawa N., Ohmiya Y., Ohkubo H., Hashimoto K., Kangawa K., Kojima M., et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun 2002, 291:884-889.
31. Tanioka T., Nakatani Y., Semmyo N., Murakami M., Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000, 275:32775-32782.
32. Watanabe K., Kurihara K., Suzuki T. Purification and characterization of membrane-bound prostaglandin E synthase from bovine heart. Biochim Biophys Acta 1999, 1439:406-414.
33. Engblom D., Saha S., Engstrom L., Westman M., Audoly L.P., Jakobsson P.J., et al. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat Neurosci 2003, 6:1137-1138.
34. Ikeda-Matsuo Y., Ota A., Fukada T., Uematsu S., Akira S., Sasaki Y. Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc Natl Acad Sci USA 2006, 103:11790-11795.
35. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
36. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091.
37. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
38. Fahmi H. mPGES-1 as a novel target for arthritis. Curr Opin Rheumatol 2004, 16:623-627.
39. Yeo S.J., Yoon J.G., Yi A.K. Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: tumor necrosis factor-alpha receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling. J Biol Chem 2003, 278:40590-40600.
40. Han R., Tsui S., Smith T.J. Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. J Biol Chem 2002, 277:16355-16364.
41. Yang T., Roder K.E., Abbruscato T.J. Evaluation of bEnd5 cell line as an in vitro model for the blood-brain barrier under normal and hypoxic/aglycemic conditions. J Pharm Sci 2007, 96:3196-3213.
42. Mestre L., Correa F., Docagne F., Clemente D., Guaza C. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 2006, 72:869-880.
43. Golech S.A., McCarron R.M., Chen Y., Bembry J., Lenz F., Mechoulam R., et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 2004, 132:87-92.
44. Mbonye U.R., Wada M., Rieke C.J., Tang H.Y., Dewitt D.L., Smith W.L. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 2006, 281:35770-35778.
45. Ridley S.H., Dean J.L., Sarsfield S.J., Brook M., Clark A.R., Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett 1998, 439:75-80.
46. Lasa M., Mahtani K.R., Finch A., Brewer G., Saklatvala J., Clark A.R. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 2000, 20:4265-4274.
47. Mifflin R.C., Saada J.I., Di Mari J.F., Adegboyega P.A., Valentich J.D., Powell D.W. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am J Physiol Cell Physiol 2002, 282:C824-C834.
48. Urade Y., Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000, 1482:259-271.
49. Hewett S.J., Bell S.C., Hewett J.A. Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacol Ther 2006, 112:335-357.
50. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57:173-185.
51. Candelario-Jalil E., Taheri S., Yang Y., Sood R., Grossetete M., Estrada E.Y., et al. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther 2007, 323:488-498.
52. de Oliveira A.C., Candelario-Jalil E., Bhatia H.S., Lieb K., Hull M., Fiebich B.L. Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia 2008, 56:844-855.
53. Murakami M., Naraba H., Tanioka T., Semmyo N., Nakatani Y., Kojima F., et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:32783-32792.
54. Saleem S., Zhuang H., de Brum-Fernandes A.J., Maruyama T., Narumiya S., Dore S. PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury. Eur J Neurosci 2007, 26:73-78.
55. Taniguchi H., Mohri I., Okabe-Arahori H., Aritake K., Wada K., Kanekiyo T., et al. Prostaglandin D2 protects neonatal mouse brain from hypoxic ischemic injury. J Neurosci 2007, 27:4303-4312.
56. Liang X., Wu L., Hand T., Andreasson K. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J Neurochem 2005, 92:477-486.
57. Ou Z., Zhao X., Labiche L.A., Strong R., Grotta J.C., Herrmann O., et al. Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2--mediated protection of brain after experimental cerebral ischemia in rat. Brain Res 2006, 1096:196-203.
58. Lin T.N., Cheung W.M., Wu J.S., Chen J.J., Lin H., Liou J.Y., et al. 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2006, 26:481-487.
59. Serhan C.N., Chiang N. Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. ScientificWorldJournal 2002, 2:169-204.
60. Scher J.U., Pillinger M.H. 15d-PGJ2: the anti-inflammatory prostaglandin?. Clin Immunol 2005, 114:100-109.
61. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999, 5:698-701.
62. Walter L., Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 2004, 141:775-785.
63. Pryce G., Baker D. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci 2005, 28:272-276.
64. Chen P., Hu S., Yao J., Moore S.A., Spector A.A., Fang X. Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res 2005, 69:28-35.
65. Pokorski M., Matysiak Z., Marczar M., Ostrpwski R.P., Kapuscinski A., Matuszewska I., et al. Brain uptake of radiolabeled N-oleoyl-dopamine in the rat. Drug Dev Res 2003, 60:217-224.
66. Gonzalez C., Almaraz L., Obeso A., Rigual R. Oxygen and acid chemoreception in the carotid body chemoreceptors. Trends Neurosci 1992, 15:146-153.
67. Strosznajder R., Pokorski Hypoxia affects arachidonic acid incorporation into phospholipids in cat carotid bodies. Eur Respir J 1995, 8(Suppl. 19).
68. Pokorski M., Strosznajder R. PO2-dependence of phospholipase C in the cat carotid body. Adv Exp Med Biol 1993, 337:191-195.
69. Karhunen T., Tilgmann C., Ulmanen I., Panula P. Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci Lett 1995, 187:57-60.
70. Cristino L., Starowicz K., De Petrocellis L., Morishita J., Ueda N., Guglielmotti V., et al. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 2008, 151:955-968.
71. Cok S.J., Morrison A.R. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001, 276:23179-23185.
72. Dixon D.A., Kaplan C.D., McIntyre T.M., Zimmerman G.A., Prescott S.M. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 2000, 275:11750-11757.